Home › Therapeutic areas › GI/Hepatology
GI/Hepatology (16 companies · 11 conditions)
Conditions
Eosinophilic Esophagitis 4 Rare Inflammatory Bowel Disease 4 Celiac Disease 3 Gastroparesis 2 Alcohol-Associated Liver Disease 1 Chronic Idiopathic Constipation 1 Irritable Bowel Syndrome with Constipation 1 Nausea and Vomiting 1 Primary Sclerosing Cholangitis 1 Rare Short Bowel Syndrome 1 Rare Wilson's Disease 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In GI/Hepatology | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABSI | Absci | DermatologyGI/Hepatology+1 | 1 | Phase 1 | $1.75B | 6 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | $619M | 8 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 2 | Phase 2 | $69.0M | 9 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 3 | $405M | 3 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | $1.39B | 9 |
| APGE | Apogee Therapeutics | DermatologyGI/Hepatology+1 Rare | 1 | Phase 2 | — | 9 |
| ARDX | Ardelyx | GI/HepatologyRenal | 2 | Approved | $724M | 4 |
| CMMB | Chemomab Therapeutics | GI/HepatologyImmunology+1 Rare | 1 | Phase 2 | $10.6M | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| ENTX | Entera Bio | GI/HepatologyMetabolic Rare | 1 | Phase 2 | $547M | 4 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 2 | Approved | $1.63B | 17 |
| FBRX | Forte Biosciences | DermatologyGI/Hepatology | 1 | Phase 2 | — | 3 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $106M | 4 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.85B | 5 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $5.4M | 7 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 2 | Approved | $231M | 27 |
No companies match.